Le Lézard
Classified in: Health, Science and technology, Business
Subject: FNC

Genelux Announces Closing of a Strategic Financing Transaction


SAN DIEGO, Sept. 25, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held clinical-stage immunotherapy company, today announced that it has entered into a convertible note and warrant financing transaction with Woodward Diversified Capital (WDC). Genelux and WDC have completed the first close of a private placement of unsecured convertible notes of up to $20M and associated warrants.

The transaction underscores the strength and promise of Olvi-Vec, Genelux's lead oncolytic immunotherapy candidate. The Company intends to use the proceeds from the financing primarily to finalize preparations for and initiate its planned Phase 3 (registration) trial of Olvi-Vec in platinum refractory/resistant ovarian cancer and  to fund  further expansion of our clinical program, and for general corporate purposes.

Gabe Woodward, Partner at WDC, commented, "We were attracted to Genelux because of the caliber of the team and because they meet our criteria of having a breakthrough and innovative approach to address a significant unmet medical need."

"Genelux is fortunate to have the financial and sophisticated strategic support of WDC as we successfully advance Olvi-Vec towards its first registration trial," said Thomas Zindrick, J.D., President and CEO of Genelux.

About Olvimulogene Nanivacirepvec (Olvi-Vec)
Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. 

About Woodward Diversified Capital
Woodward Diversified Capital provides advanced investment strategies and wealth management solutions to high net worth individuals and family offices.  The Partners of Woodward Diversified Capital have an established reputation as innovative and responsive investors, with broad transaction capabilities and a long entrepreneurial tradition of investments in a diverse range of industries.  For more information please visit www.woodwarddiversifiedcapital.com.  

About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a leader in oncolytic immunotherapy, utilizing its potent CHOICEtm discovery platform to develop a library of proprietary, oncolytic vaccinia virus-based diagnostic and therapeutic candidates.  For more information please visit www.genelux.com

Contacts
Investor Relations
Kim Duffy
info@genelux.com
(909) 307-9300

Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)
mmiller@tiberend.com
212-375-2694

Ingrid Mezo (Media)
imezo@tiberend.com
646-604-5150

SOURCE Genelux Corporation


These press releases may also interest you

at 11:48
Precision Genetics, a leading healthcare technology company and high capacity molecular testing lab, has added saliva collection to their existing portfolio of validated Covid-19 testing options submitted under Emergency Use Authorization (EUA) by...

at 11:45
SureClinical, the premier provider of FDA and EU compliance validated eClinical cloud applications today announced its complimentary support for Accelagen Pty Ltd Phase 1/2 COVID-19 trial on the SureClinical Platform. Accelagen is an Australian-based...

at 11:41
Breast, colon, prostate, and lung cancers did not stop for COVID-19 in 2020, but screenings and treatments did. Dramatically. The result, say doctors, could be a catastrophe in the making. A new study published online ahead of the November issue of...

at 11:40
More than 61 percent1 of Americans are afflicted with gastrointestinal symptoms ranging from upset stomach and diarrhea to bloating and abdominal pain. Millions of these patients are misdiagnosed, untreated, and frustrated by lack of medical insight...

at 11:39
Fighting COVID-19 is taking an undue toll on emergency physicians. A teleconference hosted on Monday, October 26 at 3:30 pm EDT by the American College of Emergency Physicians (ACEP) during ACEP20?the world's largest emergency medicine...

at 11:35
The Oncology Institute of Hope and Innovation (TOI) is proud to announce that Omkar Marathe, MD, a TOI physician, has received the "40 Under 40 in Cancer" award. The 40 Under 40 in Cancer award celebrates the contributions of emerging leaders in...



News published on 25 september 2020 at 19:00 and distributed by: